V
Vincent Servois
Researcher at Curie Institute
Publications - 158
Citations - 5641
Vincent Servois is an academic researcher from Curie Institute. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 31, co-authored 134 publications receiving 4505 citations. Previous affiliations of Vincent Servois include PSL Research University & Paris Descartes University.
Papers
More filters
Journal ArticleDOI
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
Christophe Le Tourneau,Christophe Le Tourneau,Jean Pierre Delord,Anthony Gonçalves,Céline Gavoille,Coraline Dubot,Nicolas Isambert,Mario Campone,Ol vier Trédan,Marie Ange Massiani,Cecile Mauborgne,Sebastien Armanet,Nicolas Servant,Ivan Bièche,Virginie Bernard,David Gentien,Pascal Jézéquel,Valéry Attignon,Sandrine Boyault,Anne Vincent-Salomon,Vincent Servois,Marie Paule Sablin,Maud Kamal,Xavier Paoletti,Xavier Paoletti +24 more
TL;DR: The efficacy of several molecularly targeted agents marketed in France, which were chosen on the basis of tumour molecular profiling but used outside their indications, in patients with advanced cancer for whom standard-of-care therapy had failed is assessed.
Journal ArticleDOI
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
E. Saâda-Bouzid,C. Defaucheux,Andy Karabajakian,Virginia Palomar Coloma,Vincent Servois,Xavier Paoletti,Caroline Even,Jérôme Fayette,Joël Guigay,Delphine Loirat,Frederic Peyrade,Marie Alt,Jocelyn Gal,C. Le Tourneau,C. Le Tourneau +14 more
TL;DR: Hyperprogression was observed in 29% of patients with R/M HNSCC treated with anti-PD-L1/PD-1 agents and correlated with a shorter progression-free survival (PFS), and mechanisms and causality of hyperprogression should further be assessed through prospective controlled studies.
Journal ArticleDOI
Carotid and vertebral artery dissections: three-dimensional time-of-flight MR angiography and MR imaging versus conventional angiography.
TL;DR: MR angiography is a reliable, noninvasive method for use in diagnosis and follow-up of extracranial internal carotid artery dissection, however, conventionalAngiography remains useful in vertebral artery dissections.
Journal ArticleDOI
Novel patterns of response under immunotherapy.
Edith Borcoman,Yada Kanjanapan,Stéphane Champiat,Shumei Kato,Vincent Servois,Razelle Kurzrock,Sanjay Goel,Philippe L. Bedard,C. Le Tourneau,C. Le Tourneau +9 more
TL;DR: Initially reported in advanced melanoma patients, pseudoprogression occurs when tumor index lesions regress after initial progression, supporting the concept of treating some patients beyond progression, and the classic RECIST remains a reasonable and meaningful method to assess response to immunotherapy in the clinic.
Journal ArticleDOI
NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial
Sylvie Bonvalot,Piotr L. Rutkowski,Juliette Thariat,S. Carrere,Anne Ducassou,Marie-Pierre Sunyach,P. Agoston,Angela Hong,A. Mervoyer,Marco Rastrelli,Victor Moreno,Rubi K Li,B. Tiangco,Antonio Casado Herraez,Alessandro Gronchi,László Mangel,Teresa T. Sy-Ortin,Peter Hohenberger,Thierry de Baere,Axel Le Cesne,Sylvie Helfre,Esma Saada-Bouzid,Aneta Borkowska,Rodica Anghel,Ann Co,Michaël Gebhart,Guy Kantor,Angel Montero,Herbert H. Loong,R. Verges,Lore Lapeire,Sorin Dema,Gabriel Kacso,Lyn Austen,Laurence Moureau-Zabotto,Vincent Servois,Eva Wardelmann,Philippe Terrier,Alexander J. Lazar,Judith V.M.G. Bovée,Cécile Le Péchoux,Zsusanna Papai +41 more
TL;DR: This phase 2-3 trial evaluated the safety and efficacy of the hafnium oxide (HfO2) nanoparticle NBTXR3 activated by radiotherapy versus radiotherapy alone as a pre-operative treatment in patients with locally advanced soft-tissue sarcoma and validates the mode of action of this new class of radioenhancer.